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ABSTRACT
Background Safety data are lacking on influenza
vaccination in general and on A (H1N1)v vaccination in
particular in patients with inflammatory bowel disease
(IBD) receiving immmunomodulators and/or biological
therapy.
Aims and methods The authors conducted
a multicentre observational cohort study to evaluate
symptoms associated with influenza H1N1 adjuvanted
(Pandemrix, Focetria, FluvalP) and non-adjuvanted
(Celvapan) vaccines and to assess the risk of flare of IBD
after vaccination. Patients with stable IBD treated with
immunomodulators and/or biological therapy were
recruited from November 2009 until March 2010 in 12
European countries. HarveyeBradshaw Index and Partial
Mayo Score were used to assess disease activity before
and 4 weeks after vaccination in Crohn’s disease (CD)
and ulcerative colitis (UC). Vaccination-related events up
to 7 days after vaccination were recorded.
Results Of 575 patients enrolled (407 CD, 159 UC and
nine indeterminate colitis; 53.9% female; mean age
40.3 years, SD 13.9), local and systemic symptoms were
reported by 34.6% and 15.5% of patients, respectively.
The most common local and systemic reactions were pain
in 32.8% and fatigue in 6.1% of subjects. Local symptoms
were more common with adjuvanted (39.3%) than
non-adjuvanted (3.9%) vaccines (p<0.0001), whereas
rates of systemic symptoms were similar with both types
(15.0% vs 18.4%, p¼0.44). Among the adjuvanted group,
Pandemrix more often induced local reactions than FluvalP
and Focetria (51.2% vs 27.6% and 15.4%, p<0.0001).
Solicited adverse events were not associated with any
patient characteristics, specific immunomodulatory
treatment, or biological therapy. Four weeks after
vaccination, absence of flare was observed in 377
patients with CD (96.7%) and 151 with UC (95.6%).
Conclusion Influenza A (H1N1)v vaccines are well
tolerated in patients with IBD. Non-adjuvanted vaccines
are associated with fewer local reactions. The risk of IBD
flare is probably not increased after H1N1 vaccination.
INTRODUCTION
In April 2009, the Center for Disease Control and
Prevention identiﬁed two cases of human infection
with inﬂuenza A (H1N1)v characterised by
a unique combination of gene segments that had
not been identiﬁed in human inﬂuenza A virus.1
Additional cases were rapidly reported, leading
WHO to declare a pandemic phase level 6, indi-
cating widespread human infection. This caused
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Significance of this study
What is already known about this subject?
< Patients with inflammatory bowel disease (IBD)
treated with immunomodulators and biological
therapy are a fragile population.
< Protection against influenza disease is achieved
by vaccination in immunocompetent individuals.
For immunocompromised patients (the study
sample described here), data for clinical
protection from infection are lacking. Antibody
seroconversion response is variable, with some
studies suggesting good immunogenicity and
others showing poor response.
What are the new findings?
< The types of adverse events after influenza A
H1N1 vaccination in patients with IBD are similar
to those reported in the immunocompetent
population.
< Solicited adverse events after influenza A H1N1
vaccination are not related to type of IBD or type
of immunodulators and biological therapy.
< Adjuvanted vaccines induce more local symp-
toms that non-adjuvanted vaccine in patients
with IBD receiving immunomodulatory and
biological therapy.
< In a very large majority of patients, adjuvanted
and non-adjuvanted influenza vaccines do not
affect IBD activity.
How might it impact on clinical practice in the
foreseeable future?
< This study brings new evidence on the good
safety profiles of adjuvanted and non-adjuvanted
influenza vaccines in the immunocompromised
IBD population and indicates that such vaccines
are unlikely to induce flare up in patients with
IBD. It is therefore a very important message in
case of future pandemics.
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anxiety, especially among physicians and patients who were
potentially immunocompromised. Prevention of inﬂuenza is
usually achieved by vaccination, and new vaccines directed
towards the inﬂuenza A (H1N1)v infection were manufactured.
Two larges studies have produced reassuring data on the efﬁcacy
and safety of these novel vaccines, whether in an MF59-adju-
vant form or not, in young and middle-aged adults.2 3 These data
are difﬁcult to extrapolate to other categories of people, partic-
ularly adults who have underlying immune suppression, which
is the group for whom the inﬂuenza A (H1N1)v vaccine is
particularly recommended. Patients with inﬂammatory bowel
disease (IBD) belong to a younger population, are affected with
a chronic immune-mediated inﬂammatory disorder, and are
immunocompromised to some extent when immunomodulators
such as corticosteroids, methotrexate, thiopurines and anti-
tumour necrosis factor agents are used. Because of this immu-
nosuppression, national and international recommendations and
expert advice have emphasised the need to vaccinate patients
with IBD and immunocompromised conditions against inﬂu-
enza infection.4 However, data on the global safety and efﬁcacy
of adjuvanted and non-adjuvanted vaccines are lacking in
patients with IBD.
We conducted a European multicentre prospective study to (i)
evaluate unsolicited and solicited local and systemic symptoms
associated with inﬂuenza H1N1 vaccination in patients with
IBD receiving immmunomodulatory and/or biological therapy,
(ii) compare rates and types of unsolicited and solicited local and
systemic symptoms in adjuvanted and non-adjuvanted
H1N1vaccines, (iii) assess the risk of ﬂare of IBD following
H1N1 vaccination, and (iv) search for factors associated with
increased adverse events or disease ﬂare.
METHODS
Study design
We conducted a multicentre, prospective cohort study from
November 2009 through March 2010 in 12 European countries.
Patients with IBD were recruited consecutively during outpa-
tient visits in 24 academic and non-academic IBD centres. They
were eligible if they had a stable inﬂammatory disease at the
time of the visit (left to the physician discretion), they were
treated with one or more immunomodulator and/or biological
therapy, and a single- or two-dose vaccination for H1N1 virus
was planned according to national recommendations. A stable
disease was deﬁned as one without signs of activity (biological,
endoscopic or clinical) and not requiring any treatment modiﬁ-
cation for the IBD. The only exclusion criteria were an active
inﬂammatory disease (left to the physician discretion). The type
of vaccine was decided by the national health authorities. The
vaccine was administered by intramuscular injection according
to the manufacturer ’s recommendations either by the general
practitioner or in a government vaccination centre. Patients who
had received the H1N1 vaccine before the outpatient visit were
not included. Validated clinical activity indexesdHarveye
Bradshaw Index (HBI)5 and Partial Mayo Score (PMS)6dwere
used for Crohn’s disease (CD) and ulcerative colitis (UC),
respectively, to assess disease activity (boxes 1 and 2). Data from
each patient were collected using a standardised questionnaire.
During the outpatient visit and before vaccination, all patients
were scored. Four weeks after the last dose of H1N1vaccine,
patients were contacted by phone to assess the IBD clinical
activity index and the presence of unsolicited and solicited local
(pain, redness, warmth, swelling) and systemic (shivering, fever
>388C, unusual fatigue, malaise, headache, muscle pain,
arthralgia, use of pain killers) symptoms occurring within 7 days
of vaccination. Symptoms were considered to be present or
absent. As in clinical trials,2 unsolicited and solicited events
were considered vaccine-related if occurring within 7 days of
Box 1 HarveyeBradshaw Index, a simple index of Crohn’s
disease activity
A. General well-being:
0 ¼ very well
1 ¼ slightly below par
2 ¼ poor
3 ¼ very poor
4 ¼ terrible
B. Abdominal pain:
0 ¼ none
1 ¼ mild
2 ¼ moderate
3 ¼ severe
C. Number of liquid stools per day:
D. Abdominal mass:
0 ¼ none
1 ¼ dubious
2 ¼ definite
3 ¼ definite and tender
E. Complications: (score 1 per item)
Arthralgia
Uveitis
Erythema nodosum
Aphthous ulcers
Pyoderma gangrenosum
Anal fissure
New fistula, abscess
Box 2 Partial Mayo Score, a scoring system for
assessment of ulcerative colitis activity
Stool frequency*
0 ¼ normal number of stools for this patient
1 ¼ 1e2 stools more than normal
2 ¼ 3e4 stools more than normal
3 ¼ 5 or more stools than normal
Rectal bleedingy
0 ¼ no blood seen
1 ¼ streaks of blood with stool less than half the time
2 ¼ obvious blood with stool most of the time
3 ¼ blood alone passed
Physician’s global assessmentz
0 ¼ normal
1 ¼ mild disease
2 ¼ moderate disease
3 ¼ severe disease
*Each patient served as his or her own control to establish the
degree of abnormality of the stool frequency.
yThe daily bleeding score represented the most severe bleeding
of the day.
zThe physician’s global assessment acknowledged the three
other criteria, the patient’s daily record of abdominal discomfort
and general sense of well-being, and other observations, such as
physical findings and the patient’s performance status.
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vaccination. Adverse reactions were deﬁned as any reaction that
persisted beyond 7 days after vaccination. Serious adverse reac-
tions were deﬁned as any reaction that necessitated hospital-
isation. Approval for the study protocol was obtained from the
central and local ethics committees, and the study was
conducted in accordance with the principles of the Declaration
of Helsinki. Written informed consent was obtained from each
subject. The study was scientiﬁcally supported by the European
Crohn’s and Colitis Organisation (ECCO).
Vaccines
Four vaccines directed against the 2009 H1N1 virus were used in
the study. All vaccines were non-live and licensed in the
European Union at the time of the pandemic. Three vaccines
were adjuvanted (Pandemrix, Focetria and FluvalP) and one was
non-adjuvanted (Celvapan). According to manufacturers’ and
national recommendations, either a single injection or two
injections were administered to the patients. The composition
of the vaccines differed as follows:
Pandemrix: one dose (0.5 ml) contains split inﬂuenza virus,
inactivated, containing 3.75 mg antigen equivalent to A/Cali-
fornia/7/2009 (H1N1)v-like strain (X-179A); AS03 adjuvant
composed of squalene (10.69 mg), DL-a-tocopherol (11.86 mg)
and polysorbate 80 (4.86 mg); 5 mg thiomersal (excipient).
Focetria: one dose (0.5 ml) contains 7.5 mg inﬂuenza virus
surface antigens of strain A/California/7/2009 (H1N1)v-like
strain (X-181); adjuvant MF59C.1 containing squalene 9.75 mg,
polysorbate 80 1.175 mg and sorbitan trioleate 1.175 mg.
FluvalP: one dose (0.5 ml) contains 6 mg whole virion, reassor-
tant A/California/7/2009 (H1N1)v-like strain and adjuvant
aluminium phosphate gel.
Celvapan: one dose (0.5 ml) contains whole virion inﬂuenza
vaccine, inactivated, containing 7.5 mg antigen of pandemic
strain A/California/07/2009 (H1N1)v.
Patient characteristics, side effects and disease activity
Clinical data included age, sex, pregnancy, disease duration, IBD
phenotype according to the Montreal classiﬁcation,7 type and
dosage of the immunomodulator and biological therapy, unso-
licited and solicited local and systemic symptoms. A solicited
adverse record is derived from organised data collection systems,
whereas an unsolicited adverse event is any adverse event
spontaneously reported or reported after questioning. Combined
therapy was deﬁned as the concomittant use of two or more
drugs (immunomodulators and/or biological therapy). All self-
reported reactions were recorded independently of their severity.
Number of bowel movements a day and onset of diarrhoea or
bloody diarrhoea within 7 days of vaccination were recorded.
Disease activity at baseline (before vaccination) and 4 weeks
after vaccination was assessed by the HBI and PMS in CD and
UC patients, respectively. Absence of ﬂare was deﬁned as either
decreased, unchanged or increased (by a maximum of 2 points)
clinical activity index score. For both UC and CD patients, an
increase of 3 points or more observed 4 weeks after vaccination
was considered to be a clinical ﬂare according to the liter-
ature.8e11 Additional vaccinations with seasonal inﬂuenza
vaccine and pneumococcal polysaccharide vaccine were
recorded. Dates of all vaccinations and events were noted.
Statistical analysis
Patients with incomplete data were not included in the analysis.
All statistical analysis was performed using SAS software V.9.1.
Continuous data are expressed as mean (SD) or median (IQR)
when appropriate. Qualitative data are expressed as frequency
and percentage. p<0.05 was considered signiﬁcant. To study the
relation between qualitative variables, c2 test or Fisher exact test
was performed. The difference in a continuous variable
according to a binary variable was studied using the Student t
test. Variables with p<0.2 were introduced into a stepwise
multivariate logistic regression (signiﬁcance level for entering
effects, 0.2; signiﬁcance level for removing effects, 0.05). The
stability of the model was assessed by a bootstrap method.12
The bootstrap resampling method was based on 500 replicates of
the initial dataset. Logistic multivariate regression with stepwise
selection at the 0.2 level was performed on each of these repli-
cates. The inclusion of the variable in the ﬁnal model was
conﬁrmed if this candidate variable was selected in at least 80%
of these 500 analyses.
RESULTS
Demographic, clinical characteristics and immunomodulatory
treatments of patients are given in table 1. Of 733 patients who
were eligible and signed an informed consent, 124 decided not to
receive the vaccine. A total of 609 subjects who were adminis-
tered the H1N1 vaccines were enrolled in the study, but
complete data were available for 575 subjects. An adjuvanted
vaccine was given to 499 patients, and a non-adjuvanted vaccine
to 76. A second-dose H1N1 vaccine was given to 212 patients
(66.0% and 34.0% in the adjuvanted and non-adjuvanted group,
respectively) separated by a median of 23 days. The mean age of
the subjects was 40.3 years (SD 13.9); 53.9% were women, and
six were pregnant. Of the 575 subjects, 407 had CD, 159 had
UC, and nine had indeterminate colitis. Median disease duration
was 9 years for CD (IQR 4.2e15), 7 years for UC (IQR 4e13),
and 3.5 year for indeterminate colitis (IQR 3e5). All patients
were treated with one or more immunomodulators or biological
therapy. Of the 575 patients, 41.7% were given monotherapy
and 58.3% received combined therapy. Seasonal inﬂuenza
vaccine was given additionally to 328 patients (57.0%), 68.8% of
them (n¼196) before the H1N1 vaccine (median 28 days; IQR
15e42.5) and 23.1% (n¼66) on the same day; 8.1% received
seasonal vaccination after the H1N1 vaccine (median 25 days;
IQR 11e31). Pneumococcal vaccine was administered in 12.2%
(n¼70) of all patients. The baseline characteristics were similar
among patients with adjuvanted and non-adjuvanted vaccines
except for the use of inﬂiximab, the number of H1N1 injections,
the presence of perianal disease, and the use of pneumococcal
vaccine (table 1).
Safety analysis
Solicited local and systemic reactions
Data from all 575 patients were included in safety analyses.
Solicited local and systemic reactions during the ﬁrst 7 days after
the ﬁrst dose of H1N1 vaccine are shown in table 2. Local and
systemic solicited reactions appeared mostly on the day after
vaccination, and disappeared within 48e72 h. No unsolicited
events, adverse reactions or serious adverse reactions were
reported.
The most common local reaction after any type of vaccine
was pain at the injection site, reported by 189 (32.8%) subjects.
Swelling, redness and warmth was present in 35 (6.1%), 30
(5.2%) and 10 (1.7%) patients, respectively. With the same
subtype of vaccine, patients with CD and UC had similar rates
of local symptoms. No severe local reactions were reported. Pain
was more common after injection of the adjuvanted vaccine
than with non-adjuvanted vaccine (37.3% vs 3.9%, p<0.0001).
Among the adjuvanted group, Pandemrix induced local reactions
more often than FluvalP and than Focetria (51.2% vs 27.6% and
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15.4%, p<0.0001). Patients with local reactions were younger
than patients without (mean age 38.7 (SD 13.6) vs 41.2 (SD
14.1), p¼0.039). Local symptoms were observed in 36.7% of
patients aged below 50 years old and in 28.2% of patients above
50 years (p¼0.06). Administration of seasonal inﬂuenza vaccine
did not inﬂuence the rate of local symptoms due to H1N1
vaccine (data not shown). Patients who received seasonal
vaccine and H1N1 vaccine on the same day tended to experience
more local symptoms than patients who received separated
injections (45.5% vs 37.0%, p¼0.22). In multivariate analysis,
after bootstrap resampling, the type of vaccine was the only
factor related to the rate of local solicited reactions.
The most common systemic reaction was fatigue, reported by
35 (6.1%) patients. No signiﬁcant differences in the rate of
systemic reaction were found between adjuvanted and non-
adjuvanted vaccines, although they were more common in the
Pandemrix group (21.7% vs 18.4%). A total of 17 (3.0%) subjects
reported use of pain killers. Twenty-two subjects (3.8%) reported
body temperature >388C. No severe adverse side effects were
noted. With the same subtype of vaccine, patients with CD and
UC had similar rates of systemic symptoms except fatigue,
which was more common in CD patients vaccinated with
Pandemrix (10.2% vs 1.6%, p¼0.031). Administration of
seasonal inﬂuenza vaccine at any time did not inﬂuence the rate
of systemic symptoms due to H1N1 vaccine (data not shown).
No association was found between rate of systemic symptoms
and age (p¼0.477).
Rates of any local or systemic solicited adverse events were
not associated with any speciﬁc immunomodulatory treatment
or biological therapy (data not shown). Moreover, there was no
difference in the rates of local (37.2% vs 33.6%, p¼0.38) or
systemic (18.3% vs 14.4%, p¼0.67) reactions in patients
receiving monotherapy or combined therapy.
Effect of vaccination on IBD activity
Only 3.9% of patients (16 CD and six UC) had an increase in
daily bowel movements and increased diarrhoea or bloody stools
during the ﬁrst week after H1N1vaccination. The reaction lasted
for a median of 5 days and resolved spontaneously, except in one
patient, who needed to increase corticosteroid dosage, and
another, who was started on budesonide in addition to metho-
trexate. This phenomenon was observed with all types of
Table 1 Demographic, clinical characteristics and immunomodulatory
treatments of 575 patients according to H1N1 vaccine group
All
patients
(N[575)
Adjuvanted
vaccines
(N[499)
Non-
adjuvanted
vaccine
(N[76)
p
Valuey
Demographic characteristics
Sex 0.331
Male, n (%) 263 (46.1) 224 (45.3) 39 (51.3)
Age (years), mean (SD) 40.3 (14.0) 40.4 (14.1) 40.1 (13.1) 0.892
Pregnancy, n (%) 6 (1.0) 6 (1.2) 0 (0) 1
Clinical characteristics
IBD phenotype*
CD, n (%) 407 (70.8) 348 (69.7) 59 (77.6)
UC, n (%) 159 (27.6) 142 (28.5) 17 (22.4) 0.242
IC, n (%) 9 (1.6) 9 (1.8) 0 (0)
Disease duration (years),
median (IQR)
8 (4;15) 8 (4;15) 9.5 (4;16) 0.576
Age of diagnosis
A1 53 (13.2) 46 (13.3) 7 (12.0)
A2 277 (69.1) 241 (69.4) 36 (66.7) 0.858
A3 71 (17.7) 60 (17.3) 11 (20.3)
Disease location
L1 118 (30.0) 101 (29.4) 17 (33.3)
L2 99 (25.2) 84 (24.5) 15 (29.4) 0.404
L3 176 (44.8) 158 (46.1) 18 (35.3)
L4 22 (5.5) 16 (4.7) 6 (11.1) 0.099
Disease behaviour
B1 180 (48.0) 152 (47.5) 28 (50.9)
B2 107 (28.5) 91 (28.4) 16 (29.1) 0.798
B3 88 (23.5) 77 (24.1) 11 (20.0)
p+ 102 (25.6) 95 (27.5) 7 (13.0) 0.022
Extent of UC
E1 15 (10.1) 13 (9.7) 2 (13.3)
E2 53 (35.6) 48 (35.8) 5 (33.3) 0.903
E3 81 (54.3) 73 (54.5) 8 (53.4)
Immunomodulatory treatments
Corticosteroids, n (%) 65 (11.3) 52 (10.4) 13 (17.1) 0.086
Azathioprine/6MP, n (%) 319 (55.5) 274 (54.9) 45 (59.2) 0.482
Methotrexate, n (%) 39 (6.8) 36 (7.2) 3 (3.9) 0.289
Anti-TNF therapies, n (%) 280 (48.7) 251 (50.3) 29 (38.2) 0.048
Infliximab, n (%) 171 (29.7) 157 (31.5) 14 (18.4) 0.02
Adalimumab, n (%) 98 (17) 84 (16.8) 14 (18.4) 0.732
Certolizumab, n (%) 11 (1.9) 9 (1.8) 2 (2.6) 0.646
Calcineurin inhibitors, n (%) 3 (0.5) 3 (0.6) 0 (0) 1
Others, n (%) 13 (2.3) 8 (1.6) 5 (6.6) 0.019
Monotherapy, n (%) 240 (41.7) 205 (41.1) 35 (46.1) 0.413
Receipt of additional vaccines
H1N1 booster (2nd injection), n (%) 212 (36.9) 140 (28.1) 72 (94.7) 0.001
Seasonal influenza vaccine, n (%) 328 (57) 291 (58.3) 37 (48.7) 0.114
Pneumococcal vaccine, n (%) 70 (12.2) 68 (13.6) 2 (2.6) 0.006
Adjuvanted vaccines are Pandemrix, Focetria and FluvalP. Non-adjuvanted vaccine is
Celvapan.
*According to Montreal classification.
yDepicts difference between adjuvanted vaccines and non-adjuvanted vaccine.
CD, Crohn’s disease; IBD, inflammatory bowel disease; IC, indeterminate colitis; TNF,
tumour necrosis factor; UC, ulcerative colitis; 6-MP, 6 mercaptopurine.
Table 2 Solicited local and systemic adverse effects within 7 days of
receipt of first dose of adjuvanted or non-adjuvanted vaccines
Effect
Adjuvanted vaccine
Non-
adjuvanted
vaccine
Pandemrix
(AS03)
(N[295)
Focetria
(MF59)
(N[175)
FluvalP
(aluminium
phosphate)
(N[29)
Celvapan
(N[76)
Local reaction
Any reaction, n (%) 160 (54.2) 28 (16.0) 8 (27.6) 3 (3.9)
Pain, n (%) 151 (51.2) 27 (15.4) 8 (27.6) 3 (3.9)
Redness, n (%) 26 (8.8) 4 (2.3) 0 (0) 0 (0)
Warmth, n (%) 10 (3.4) 0 (0) 0 (0) 0 (0)
Swelling, n (%) 33 (11.2) 2 (1.1) 0 (0) 0 (0)
Systemic reaction
Any reaction, n (%) 64 (21.7) 11 (6.3) 0 (0) 14 (18.4)
Shivering, n (%) 3 (1.0) 1 (0.6) 0 (0) 0 (0)
Fever $388C, n (%) 16 (5.4) 2 (1.1) 0 (0) 4 (5.3)
Unusual fatigue, n (%) 24 (8.1) 4 (2.3) 0 (0) 7 (9.2)
Malaise, n (%) 19 (6.4) 1 (0.6) 0 (0) 5 (6.6)
Headache, n (%) 17 (5.8) 3 (1.7) 0 (0) 1 (1.3)
Muscle pain, n (%) 15 (5.1) 3 (1.7) 0 (0) 0 (0)
Arthralgia, n (%) 5 (1.7) 1 (0.6) 0 (0) 1 (1.3)
Use of pain killers, n (%) 16 (5.4) 0 (0) 0 (0) 1 (1.3)
Increased bowel movements per day, diarrhoea and/or bloody diarrhoea
Any IBD, n (%) 10 (3.4) 5 (2.9) 0 (0) 7 (9.2)
Crohn’s disease, n 8 3 0 5
Ulcerative colitis, n 2 2 0 2
Indeterminate colitis, n 0 0 0 0
IBD, inflammatory bowel disease.
Gut 2011;60:456e462. doi:10.1136/gut.2010.233981 459
Inflammatory bowel disease
 o
n
 26 June 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gut.2010.233981 on 26 January 2011. Downloaded from
 
vaccine except FluvalP, and was more common with Celvapan
than with adjuvanted vaccines (9.2% vs 3.0%, p¼0.018). Of the
15 patients who received the adjuvanted vaccines, nine had
symptoms after the ﬁrst dose and six after the second dose,
whereas all seven patients vaccinated with Celvapan, the
non-adjuvanted vaccine, had symptoms after the ﬁrst dose.
Interestingly, six of these patients received a second dose of
Celvapan and tolerated the second injection well. Immuno-
modulatory treatments or biological therapy did not inﬂuence
the occurrence of such adverse reaction. CD and UC patients
were similarly affected (3.9% vs 3.8%, p¼0.93). Of note,
occurrence of these symptoms was independent of the age of
patients.
Data on follow-up disease activity were available for 554
patients and are given in table 3. Patients were scored at baseline
and 4 weeks (median 31 days; IQR 28e37) after the last
administration of H1N1 vaccine. The median disease activity
score at baseline was 1 (IQR 0e3) and 1 (IQR 0e2) for CD and
UC, respectively. Thirty-four CD patients (8.7%) had a HBI
score above 5 points, and 22 UC patients (13.9%) had a PMS
above 3 points. Four weeks after the last vaccination, absence of
ﬂare was observed in 377 patients with CD (96.7%) and 151
with UC (95.6%). Thirteen CD patients (3.3%) had a median
rise of 5 (IQR 4e7) points, and seven UC (4.4%) patients had
a median rise of 3 (IQR 3e5) points. Evolution of disease activity
in patients with slightly higher scores at baseline was similar to
those with the lowest score (data not shown). Increase in disease
activity was not related to type of vaccine (p¼0.33) or type of
IBD (p¼0.20).
Of the 22 patients who experienced increased daily bowel
movements, diarrhoea or bloody diarrhoea during the ﬁrst week
after vaccination, three of the 19 for whom data were available
(15.8%) had an increase of 3 or more points in their disease
activity score 4 weeks after vaccination. UC patients were more
likely than CD patients to keep an increased disease activity (one
CD and two UC).
DISCUSSION
During last winter, the availability of vaccines against inﬂuenza
H1N1v infection across Europe was variable. Most European
countries used the adjuvanted forms of the vaccine, with
composition and type of adjuvants varying from one vaccine to
another. The use of adjuvanted and non-adjuvanted inﬂuenza
vaccines in general had never been investigated in a large cohort
of patients with IBD. The number of subjects included in the
study allowed us to estimate the frequency of local and systemic
reactions with good precision. The safety and tolerability
proﬁles of adjuvanted and non-adjuvanted inﬂuenza vaccines
were favourable in this large cohort of patients. In our study,
more than half of patients with IBD additionally received the
seasonal inﬂuenza vaccine according to the European recom-
mendations at the time of the pandemic. However, we observed
a very low rate of pneumococcal vaccination despite recom-
mendations and the well-known pneumococcal pneumonia
complications that occur after inﬂuenza infection. Our study
may underestimate the true percentage of pneumococcal vacci-
nation, as some patients may have received this vaccine a few
years before the study.
The side effect proﬁle of H1N1 vaccines in immunocompro-
mised patients with IBD, particularly the type of solicited adverse
events, is consistent with previous reports in the immunocom-
petent population.2 The most common local symptom observed
with all types of vaccine was pain at the injection site, as
observed with other studies in immunocompetent subjects.2 3 13
Other local symptoms were otherwise rare. Systemic symptoms
such as unusual fatigue, myalgia, headache and malaise were
found similarly to previous reports in the immunocompetent
population, although large variations exist and correlate mostly
with the type of vaccine. This indicates that the reactions seen in
patients with IBD are similar to those expected in the general
population and are not inﬂuenced by either the inﬂammatory
intestinal disease itself or any immunomodulatory treatment or
biological therapy. However, direct comparison of the tolerance
between immunocompetent and immunocompromised patients
is not easy. We did not observe any association between any
immunomodulatory treatment or biological therapy and the rate
of local or systemic symptoms. As expected, administration of
adjuvanted vaccines was associated with an increased incidence
of solicited local reactions, which were all transient, as classically
reported by previous studies.14e17 In multivariate analysis, only
the type of vaccine correlated with rate of local symptoms.
Surprisingly, we observed important variations in terms of soli-
cited local reactions within the adjuvanted group. Pandemrix,
Focetria and FluvalP differ in composition in terms of viral strain
doses and the type of adjuvant used. This may account for these
differences. We found, like others,13 that administration of
seasonal inﬂuenza on the same day as the H1N1 vaccine led to
more local symptoms. Systemic reactions were observed similarly
in patients receiving adjuvanted or non-adjuvanted vaccines,
although headache, arthralgia, muscle pain and use of pain killers
were more common with Pandemrix than with non-adjuvanted
vaccine. In trials comparing systemic symptoms in non-adju-
vanted and MF59-adjuvanted vaccines, no signiﬁcant difference
in frequency or severity was observed.2 In our study, systemic
reactions were observed in 89 of 575 patients (15.5%). Observed
rates of systemic symptoms were similar with adjuvanted and
non-adjuvanted vaccines (15.0% vs 18.4%). The 95% CI for the
difference was 12% to 6%, and therefore our trial may not have
enough power to highlight differences between the adjuvanted
and non-adjuvanted group. Gastrointestinal symptoms occurring
within 7 days of vaccination were much more common with
Celvapan than with adjuvanted vaccines. The European Medi-
cines Agency indicated recently that gastrointestinal symptoms
such as nausea, diarrhoea and abdominal pain were common
($1/100 to <1/10) with Celvapan and uncommon ($1/1000 to
<1/100) with Pandemrix or Focetria in non-IBD immunocom-
petent patients.18 These symptoms, also observed in our cohort,
may therefore not be related to IBD but to the vaccine itself.
Regular concerns, particularly in patients with immune-
mediated inﬂammatory disease (IMID), arise around adjuvanted
vaccines despite numerous data showing a good safety proﬁle.19
Part of clinicians’ concerns about the safety of vaccination in
IMID originated from a number of case reports suggesting an
effect of vaccination on IMID onset or course.20 These publi-
cations led to a belief among some clinicians that vaccination
Table 3 Evolution of clinical inflammatory bowel disease (IBD) score
4 weeks after vaccination
IBD clinical score activity CD (N[390) UC (N[158) IC (N[6)
HBI at baseline, median (IQR) 1 (0;3) e e
PMS at baseline, median (IQR) e 1 (0;2) 1 (0;2)
Absence of flare, n (%) 377 (96.7) 151 (95.6) 5 (83.3)
Rise of 3 points, n (%) 1 (0.2) 4 (2.5) 0 (0)
Rise of 4 points, n (%) 3 (0.8) 1 (0.6) 1 (16.7)
Rise of $ 4 points, n (%) 9 (2.3) 2 (1.3) 0 (0)
CD, Crohn’s disease; HBI, HarveyeBradshaw Index; IC, indeterminate colitis; PMS, Partial
Mayo Score; UC, ulcerative colitis.
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might trigger a ﬂare of the underlying IMID. Live vaccines are
generally contraindicated in immunocompromised patients, so
reports dealing with their effect on disease activity are rare. In
a relatively small retrospective study, measlese
mumpserubella booster vaccination in children with juvenile
idiopathic arthritis appeared safe, as vaccination did not induce
infection, nor did it signiﬁcantly increase disease activity or
medication use.21 22 For non-live vaccines, substantial literature
data support the conclusion that immunisation of IMID
patients does not increase clinical or laboratory parameters of
disease activity.23 Most of this evidence comes from medium-
sized controlled trials in which disease activity was mostly
assessed from general clinical symptoms and pain scores. Some
studies also used standardised clinical disease activity scores such
as the Systemic Lupus Erythematosus Disease Activity Index24
and the Disease Activity Score in rheumatoid arthritis.25 We
provide new information on the effect of adjuvanted and non-
adjuvanted inﬂuenza vaccines on the IBD activity. Two studies
have shown the effect of inﬂuenza vaccination in 51 and 146
paediatric and young adult patients with IBD. They did not
show modiﬁcation of disease activity after administration of
trivalent inﬂuenza non-adjuvanted vaccine.26 27 Although
imperfect, clinical scores such as HBI and PMS are useful tools in
clinical trials. In our cohort, before vaccination, all patients had
a stable inﬂammatory disease. This was left to the physician
discretion, but was also well reﬂected by the low HBI and PMS
values obtained at baseline. In CD, a decrease of 3 points in the
HBI score is recognised as response to therapy.8 In previous
studies, it has been shown that the PMS performed as well as
the full Mayo Score in identifying clinical response.9 However,
criteria for deﬁning a response in UC is less clear, as authors
identify a change of 2, 2.5 or 3 points in the PMS as a signiﬁcant
response.9 11 Hence, in our study, an increase of 3 points for
either HBI or PMS was considered a signiﬁcant ﬂare. With these
criteria, only a minority of patients had an increased score
4 weeks after vaccination. In these patients, the ﬂare up was not
related to either type of IBD or type of vaccine administered. If
an increase of 2 points in the PMS is considered as clinically
signiﬁcant, the percentage of UC patients with a stable disease
4 weeks after H1N1 vaccination falls slightly from 95.6% to
93.7%. Therefore, no matter the criteria used to deﬁne clinical
ﬂare in UC, in the vast majority of patients with UC, disease
activity appears to remain stable after vaccination. Taken
together, our results indicate that the risk/beneﬁt ratio of
inﬂuenza vaccination in patients with IBD treated with
immunomodulators and biological therapy is probably highly in
favour of a vaccination strategy.
There are some limitations of this study. The main one
concerns the assessment of HBI and PMS by phone 4 weeks after
the vaccine. Physical conﬁrmation was not possible, but we
believe that the effect of this limitation is low. Indeed, when
a largemodiﬁcation of the physical examination occurs, it is often
accompanied by new symptoms, and we assume that signiﬁcant
modiﬁcation had therefore been reported. However, use of
phone records may lead to underestimation or overestimation of
these clinical scores. The second limitation concerns the
confounding bias (unrelated to vaccine administration) regarding
an increased score 4 weeks after receipt of the vaccine. We cannot
rule out the possibility of drugs, non-steroidal anti-inﬂammatory
drugs, viral or bacterial digestive infection, or stress being
responsible for increasing the score 4 weeks after vaccination.
In conclusion, our results support the good safety proﬁle of
adjuvanted and non-adjuvanted inﬂuenza vaccine in patients
with IBD and bring new evidence that use of adjuvanted vaccine
has few or no effects on IBD activity. Nevertheless, deﬁnitive
conclusions can only be derived from well-conducted, rando-
mised, placebo controlled trials or large registries. However, this
study provides evidence that adjuvanted and non-adjuvanted
inﬂuenza vaccines are unlikely to induce re-activation in patients
with IBD and will help us to manage large distributions of
adjuvanted or non-adjuvanted vaccines in the case of further
pandemics.
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